MedPath

Fecal microbiota

Generic Name
Fecal microbiota
Brand Names
Rebyota, VOWST
Drug Type
Biotech
Unique Ingredient Identifier
Q805XO2F7C

Overview

Fecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of Clostridioides difficile infection (CDI) in patients given an antibacterial treatment for recurrent CDI. Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge. Recurrent CDI has a high risk of mortality and a high failure rate. The use of fecal microbiota transplantation is a treatment alternative for patients with recurrent CDI, also associated with lower costs and patient waiting times. For this type of therapy to be efficient, qualified donors must be selected. Human fecal matter is then tested for a panel of transmissible pathogens and processed with methods aimed at preserving bacterial viability. The purpose of fecal microbiota transplantation is to restore gut microbiota and replace microbes with healthy host microbiota. REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022. In April 2023, the agency also approved VOWST, a capsule formulation of live fecal microbiota spores for oral administration.

Background

Fecal microbiota, given either as a rectal transplant or in an oral formulation of live spores, is an FDA-approved option to prevent the recurrence of Clostridioides difficile infection (CDI) in patients given an antibacterial treatment for recurrent CDI. Although the incidence of CDI has declined and the number of cases requiring hospitalization has been lower over the years, the recurrence of CDI still represents a challenge. Recurrent CDI has a high risk of mortality and a high failure rate. The use of fecal microbiota transplantation is a treatment alternative for patients with recurrent CDI, also associated with lower costs and patient waiting times. For this type of therapy to be efficient, qualified donors must be selected. Human fecal matter is then tested for a panel of transmissible pathogens and processed with methods aimed at preserving bacterial viability. The purpose of fecal microbiota transplantation is to restore gut microbiota and replace microbes with healthy host microbiota. REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022. In April 2023, the agency also approved VOWST, a capsule formulation of live fecal microbiota spores for oral administration.

Indication

Fecal microbiota is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Associated Conditions

  • Clostridioides Difficile Infection Recurrence

Clinical Trials

Phase 1
Recruiting
Posted: 2023/06/23
Sponsor:
Peking University Si...
Not Applicable
Completed
Posted: 2017/10/12
Sponsor:
The Second Hospital ...
Phase 2
Terminated
Posted: 2017/09/13
Sponsor:
Psychiatric Hospital...

FDA Approved Products

VOWST
Manufacturer:Aimmune Therapeutics, Inc.
Route:ORAL
Strength:30000000 [CFU] in 1 1
Approved: 2023/04/21
NDC:71881-400
Rebyota
Manufacturer:Ferring Pharmaceuticals Inc.
Route:RECTAL
Strength:50000000000 [CFU] in 150 mL
Approved: 2022/11/30
NDC:55566-9800

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath